| Baculovirus expression of functional P210 BCR-ABL oncogene product. | None |
| BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene. | None |
| MAPK15 mediates BCR-ABL1-induced autophagy and regulates oncogene-dependent cell proliferation and tumor formation. | None |
| WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene. | None |
| Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. | None |
| An oncogene-Bcr-Abl-has been demonstrated to drive such a mechanism that up-regulates the expression of a functionally important target gene, SMS1. | None |
| cDNA sequence for human bcr, the gene that translocates to the abl oncogene in chronic myeloid leukaemia. | None |
| Only IGLV3-21*01 facilitates effective homotypic BCR-BCR interaction that results in autonomous, oncogenic BCR signaling after acquiring R110 as a single-point mutation. | None |
| Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures. | None |
| Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. | None |
| Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. | None |
| Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. | None |
| Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. | None |
| In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. | None |
| Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity. | None |
| Induction of protein-tyrosine-phosphatase activity by interleukin 6 in M1 myeloblastic cells and analysis of possible counteractions by the BCR-ABL oncogene. | None |
| The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion. | None |
| The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3 kinase pathway. | None |
| [The role of p21ras oncoprotein in signal transduction mediated through B cell antigen receptor (BCR)]. | None |
| Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein. | None |